Kestra Medical Technologies (NASDAQ:KMTS) CFO Vaseem Mahboob Sells 26,287 Shares

Kestra Medical Technologies, Ltd. (NASDAQ:KMTS) CFO Vaseem Mahboob sold 26,287 shares of the firm’s stock in a transaction dated Friday, August 7th. The shares were sold at an average price of $25.88, for a total value of $680,307.56. Following the sale, the chief financial officer directly owned 60,609 shares in the company, valued at approximately $1,568,560.92. This represents a 30.25% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link.

Vaseem Mahboob also recently made the following trade(s):

• On Tuesday, August 4th, Vaseem Mahboob sold 6,995 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $24.68, for a total value of $172,636.60.
• On Monday, August 3rd, Vaseem Mahboob sold 5,391 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $23.80, for a total value of $128,305.80.
• On Friday, July 31st, Vaseem Mahboob sold 8,817 shares of Kestra Medical Technologies stock. The stock was sold at an average price of $22.61, for a total value of $199,352.37.
• On Thursday, July 30th, Vaseem Mahboob sold 3,980 shares of Kestra Medical Technologies stock. The shares were sold at an average price of $22.75, for a total value of $90,545.00.

Kestra Medical Technologies Stock Down 1.6%

NASDAQ KMTS opened at $27.90 on Wednesday. Kestra Medical Technologies, Ltd. has a 12 month low of $14.40 and a 12 month high of $30.00. The company has a current ratio of 4.41, a quick ratio of 4.41 and a debt-to-equity ratio of 0.16. The stock has a market cap of $1.63 billion, a PE ratio of -11.53 and a beta of 0.58. The stock’s 50 day moving average is $23.31 and its 200 day moving average is $22.63.

Kestra Medical Technologies (NASDAQ:KMTS) last announced its quarterly earnings data on Tuesday, July 14th. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.59) by ($0.08). The company had revenue of $28.64 million for the quarter. Kestra Medical Technologies had a negative net margin of 138.35% and a negative return on equity of 57.38%. Research analysts predict that Kestra Medical Technologies, Ltd. will post -2.29 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of analysts have issued reports on KMTS shares. JPMorgan Chase & Co. began coverage on shares of Kestra Medical Technologies in a report on Monday. They issued an “overweight” rating and a $30.00 price target on the stock. Oppenheimer initiated coverage on shares of Kestra Medical Technologies in a report on Tuesday, July 21st. They set a “market perform” rating for the company. Wall Street Zen upgraded Kestra Medical Technologies from a “sell” rating to a “hold” rating in a research report on Saturday. BTIG Research lifted their target price on Kestra Medical Technologies from $30.00 to $32.00 and gave the stock a “buy” rating in a report on Wednesday, July 15th. Finally, Wolfe Research set a $30.00 target price on Kestra Medical Technologies in a research report on Wednesday, July 15th. Four investment analysts have rated the stock with a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, Kestra Medical Technologies presently has an average rating of “Hold” and an average target price of $28.14.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently modified their holdings of KMTS. Russell Investments Group Ltd. raised its stake in Kestra Medical Technologies by 43.5% during the fourth quarter. Russell Investments Group Ltd. now owns 1,563 shares of the company’s stock valued at $41,000 after purchasing an additional 474 shares in the last quarter. Brown Brothers Harriman & Co. lifted its position in Kestra Medical Technologies by 26.8% during the third quarter. Brown Brothers Harriman & Co. now owns 3,104 shares of the company’s stock valued at $74,000 after purchasing an additional 656 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Kestra Medical Technologies by 7.3% in the 3rd quarter. Rhumbline Advisers now owns 12,925 shares of the company’s stock worth $307,000 after buying an additional 874 shares in the last quarter. Farther Finance Advisors LLC bought a new stake in shares of Kestra Medical Technologies in the 4th quarter worth about $31,000. Finally, Police & Firemen s Retirement System of New Jersey increased its holdings in shares of Kestra Medical Technologies by 34.6% in the 4th quarter. Police & Firemen s Retirement System of New Jersey now owns 5,420 shares of the company’s stock worth $144,000 after buying an additional 1,392 shares during the last quarter.

About Kestra Medical Technologies

We are a commercial-stage, wearable medical device and digital healthcare company focused on transforming patient outcomes in cardiovascular disease using monitoring and therapeutic intervention technologies that are intuitive, intelligent, and connected. We have developed and are commercializing our Cardiac Recovery System platform, a comprehensive and advanced system that integrates monitoring, therapeutic treatment, digital health, and patient support services into a single, unified solution. The cornerstone of our Cardiac Recovery System platform is the ASSURE WCD, a next generation wearable cardioverter defibrillator (“WCD”) used to protect patients at an elevated risk of sudden cardiac arrest (“SCA”), a major public health problem that accounts for approximately 50% of all cardiovascular deaths in the U.S.